Earnings Call Summary | Cutera(CUTR.US) Q1 2024 Earnings Conference
Earnings Call Summary | Cutera(CUTR.US) Q1 2024 Earnings Conference
The following is a summary of the Cutera, Inc. (CUTR) Q1 2024 Earnings Call Transcript:
以下是Cutera, Inc.（CUTR）2024年第一季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Cutera reported Q1 revenue of $38.8 million, a decrease from both the same period in 2023 and Q4 of 2023.
The gross margin rate also declined to 38.2% compared to 43.5% for the same period the previous year.
Non-GAAP loss from operations increased to $20.4 million in Q1 2024.
Cash balance decreased to $105.4 million.
Cutera公佈的第一季度收入爲3,880萬美元，較2023年同期和2023年第四季度均有所下降。
毛利率也下降至38.2％，而去年同期爲43.5％。
2024年第一季度，非公認會計准則運營虧損增加至2,040萬美元。
現金餘額下降至1.054億美元。
Business Progress:
業務進展：
Cutera launched the AviClear technology and xeo+ to the North American market, both of which received positive feedback.
Major focus areas for Cutera include operational excellence, customer partnerships, revenue maintenance, and field force expansion.
Cutera is exploring the Australian market for AviClear and is investing in its clinical expansion.
Despite a decline in body contouring sales due to GLP-1 drugs, Cutera expects a resurgence as these temporary effects subside.
Cutera向北美市場推出了AviClear技術和xeo+，兩者都獲得了積極的反饋。
Cutera的主要重點領域包括卓越運營、客戶夥伴關係、收入維持和現場部隊擴張。
Cutera正在探索AviClear的澳大利亞市場，並正在投資其臨床擴張。
儘管由於 GLP-1 藥物，塑身產品的銷量有所下降，但Cutera預計，隨着這些暫時效應的消退，塑身產品的銷量將捲土重來。
More details: Cutera IR
更多詳情： Cutera IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。